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Integrin 
 
 
 
E
 
 
 
7 (CD103) has been an enigmatic and tan-
talizing molecule (1). The history of experiments on its
 
functional significance is a record of promise and disappoint-
ment in equal measure. CD103 has been considered to
have a role mainly or exclusively in the mucosal immune
system, but this supposition now needs to be reappraised.
The molecule is expressed at high levels by mucosal T cells,
especially the CD8
 
 
 
 population in the epithelium of the
gut, but is found on small subsets of T cells elsewhere. It is
also present on mucosal mast cells and mucosal dendritic
APCs. This eccentric pattern of expression has recently
been extended to include splenic CD4
 
 
 
 CD25
 
 
 
 Treg cells,
 
 
 
30% of which are CD103
 
 
 
 (2). A plausible explanation
for the expression profile is that the 
 
 
 
E subunit is transcrip-
tionally regulated by transforming growth factor (TGF)-
 
 
 
.
In fact, no other stimulus has consistently been shown to
induce expression. Thus, CD103 is found on T cells resid-
ing in tissue microenvironments where bioactive TGF-
 
 
 
 is
abundant. This is often the case in the vicinity of epithelia
and in situations in which chronic inflammation is taking
place. The particular association of CD103
 
 
 
 cells with epi-
thelia is also explained by the fact that its principal ligand is
E-cadherin, an epithelial homophilic adhesion molecule.
The relationships between the integrins discussed here and
their ligands are shown in Table I.
Studies on CD103 function have, until now, met with
mixed fortunes. Like other integrins, when ligated it pro-
vides costimulation for T cell proliferation and effector
function. Importantly, the interaction between CD103 and
E-cadherin will substitute for that between lymphocyte
function–associated antigen (LFA)-1 and intercellular adhe-
sion molecule (ICAM)-1 in CD8
 
 
 
-mediated CTL effector
 
function (3). This could be especially significant for epi-
thelial target cells, which often lack ICAM-1. It has been
suggested that CD103 could function as a homing receptor
encouraging T cells to extravasate to the gut. However, the
balance of evidence more clearly favors a role in retention
or microlocalization of T cells in the vicinity of epithelia
rather than in mucosal-specific homing. In contrast, the sis-
ter integrin of CD103, 
 
 
 
4
 
 
 
7, is known to play an impor-
tant role in the homing of leukocytes to mucosal sites. Ini-
tial studies on the CD103
 
 
 
/
 
 
 
 mouse were somewhat
disappointing in that the only noticeable change was a
modest reduction in the numbers of mucosal T cells and a
T cell–dependent dermatitis of unknown etiology (4–6).
 
An Unexpected Role for CD103 in Allograft Rejection.
 
The paper by Feng et al. (7) in this issue is the first clear-cut
demonstration that CD103 can have a pivotal role in T cell
effector function in vivo, specifically in allograft rejection.
The authors have shown that CD103
 
 
 
/
 
 
 
 Balb/c mice can-
not reject A/J strain islet allografts implanted under the kid-
ney capsule. Adoptive transfer experiments indicated that
the defect was in the CD8
 
 
 
 T cell population. In other re-
spects, CD8
 
 
 
 CD103
 
 
 
/
 
 
 
 cells were immunologically com-
petent and responded normally in vitro to A/J cells by pro-
ducing IFN-
 
 
 
 and generating CTL which lysed target
lymphoblasts effectively. Moreover, CD8
 
 
 
 CD103
 
 
 
/
 
 
 
 
 
cells
could accumulate efficiently around islet grafts and so had
no intrinsic defect in their capacity to exit the vasculature.
Indeed, at the stage when rejection would normally be al-
most complete (day 14), the grafts were surrounded by a
halo of activated T cells seemingly unable to enter the islets.
Although one cannot entirely rule out the possibility that
development of CD8
 
 
 
 effector T cells was in some way ab-
normal in CD103
 
 
 
/
 
 
 
 mice or that the cells were restrained
by a regulatory population, there appeared to be no defect
in sensitization. What then is the role of CD103 in rejec-
tion of islet grafts and is this study relevant to the broader
context of allotransplantation and autoimmune disease?
 
Examination of the cell population infiltrating islet allografts
undergoing rejection in control mice showed that about
half of the cells expressed CD8 and only a minority were
CD103
 
 
 
. The finding that such a small proportion of
CD103
 
 
 
 cells, 
 
 
 
10% of the total infiltrate, trigger the re-
jection mechanism at first sight seems surprising. The most
straightforward explanation was that CD8
 
 
 
 CD103
 
 
 
 T
cells have a ‘pathfinder’ role in promoting entry of effector
cells into the islets. Thus, engagement of E-cadherin on is-
let cells, which are known to express this molecule (8), may
directly or indirectly trigger local secretion of chemoattrac-
tants. This could occur through a costimulatory effect of
the integrin acting in concert with recognition of cognate
alloantigen by the TCR. CD8
 
 
 
 cells are known to secrete
chemokines of the CXC and CC family (9). In addition,
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IFN-
 
 
 
 derived from the CD8
 
 
 
 T cells could induce
chemokine secretion from islet 
 
 
 
 cells themselves (10). A
more significant factor might be the induction of ICAM-1
on the islet cells. Other T cell populations, both CD8
 
 
 
 and
CD4
 
 
 
, would then be drawn to the site and cause islet cell
death through the concerted action of IFN-
 
 
 
 and perforin
or Fas-mediated mechanisms. Alternatively, the primary
event could be direct cytotoxic lysis of islet cells by a small
cohort of CD103
 
 
 
 CD8
 
 
 
 cells that accumulate in the graft
by adhesion to E-cadherin on islet cells. Infiltration of other
T cells would then follow as a secondary phenomenon.
 
Are Islets a Special Case?
 
Why should CD103 be so sig-
nificant in the case of islet grafts? The importance of adhe-
sion between immune effector cells and their targets is well
known. The interaction between LFA-1 on the T cell and
ICAM-1 on its target holds the cells in intimate apposition
and provides crucial costimulatory signals for the organiza-
tion of the immune synapse which focuses killing mecha-
nisms (11, 12). Is the interaction between LFA-1 and
ICAM-1 available in the case of islet allografts? One suspects
not, at least not at first. Feng et al. demonstrated that LFA-1
was expressed by the activated CD8
 
 
 
 cells surrounding the
graft but did not examine the islet allografts for ICAM-1.
Previous studies show that ICAM-1 can be induced on islet
cells by inflammatory cytokines (13) but that it is normally
absent, as are ICAM-2 and -3. ICAM-4 and -5 would not
be expected to be involved here because of their known tis-
sue specificity. Therefore, it is probable that an LFA-1–
ICAM interaction is not available for effector CD8
 
 
 
 T cells
to initiate the rejection process but that ICAM-1 is induced
after infiltration by the first cohort of CD103
 
 
 
 cells (14).
Thus, interaction between CD103 on CD8
 
 
 
 T cells and
E-cadherin on islet cells would provide an alternative, cru-
cial, integrin/ligand pair for accumulation of CD8
 
 
 
 cells and
their costimulation within the graft. There is no evidence
that CD103 has any unique signaling properties that cannot
be provided by LFA-1. It should be noted that inhibition of
LFA-1 and VLA-4 can also effectively prolong islet allograft
survival (15). This can be partly explained by a role for these
molecules in extravasation of inflammatory cells, which re-
quires recognition of their respective endothelial ligands,
ICAM-1 or -2 and vascular cell adhesion molecule
(VCAM)-1, and also a function in a second wave of infiltra-
tion into the islets that is CD103 independent. Unlike the
situation with CD103, initial sensitization to graft antigens
may also be inhibited by blocking these other integrins.
 
In contrast to the acceptance of islet allografts by CD103
 
 
 
/
 
 
 
mice, Feng et al. (7) showed that skin allografts were rejected
normally and that rejection occurred by T cell infiltration
into the dermis and vascular bed, not the epithelium. Thus,
CD103 would not be involved. In fact, it is possible that an-
other reason Feng et al. observed such a dramatic effect of
CD103 deficiency on pancreatic allograft rejection was their
use of highly purified islet cell preparations free of vascular
and ductal tissue. This, coupled with the use of an indicator
of rejection (blood glucose levels) that depends on the func-
tion of the islet cells themselves, may have limited the poten-
tial to observe pathology involving CD103-independent
mechanisms. One wonders if reduced purity of some trans-
planted islet preparations could account for the subset of
CD103
 
 
 
/
 
 
 
 mice that were able to reject the allografts.
 
Significance of TGF-
 
 
 
.
 
Previous studies from G.A. Had-
ley’s laboratory (16) have shown that TGF-
 
 
 
 produced
during allostimulation of T cells in vitro induces CD103
expression on a proportion of effector CD8
 
 
 
 T cells. It
should also be noted that TGF-
 
 
 
 is important for the de-
velopment and function of islet cells and is produced by
them (17). So this local source of TGF-
 
 
 
 may contribute
to the induction or maintenance of CD103 expression on
T cells in the vicinity of the graft.
 
Implications for Transplantation in a Broader Context and for
Autoimmune Disease.
 
Two groups have reported that T
cells infiltrating the tubular epithelium of renal allografts
undergoing late rejection crises express CD103 (18, 19). A
positive correlation was reported between the severity of
tubulitis, the prevalence of CD8
 
 
 
 CD103
 
 
 
 T cells and the
local production of TGF-
 
 
 
 by the epithelium. Similarly, in
Sjogren’s syndrome, an autoimmune disease affecting exo-
crine glands, CD8
 
 
 
 CD103
 
 
 
 T cells are found in close as-
sociation with the acinar and ductal epithelia, the focus of
tissue damage (20). It is enticing to speculate that blocking
E-cadherin recognition by CD103 could reduce the epi-
thelial pathology in these two situations. The feasibility de-
pends on the availability of other costimulatory pathways
between the T cell and the epithelium, especially LFA-1–
ICAM-1, which in the case of Sjogren’s syndrome may be
minimal (20). The role of CD103 in inflammatory bowel
disease is not yet properly resolved. In mouse colitis evoked
by TNP, treatment with anti-CD103 antibodies amelio-
rates the disease (21) but 
 
 
 
7 integrins are not necessary for
the development of colitis in IL-2
 
 
 
/
 
 
 
 mice or after transfer
of CD4
 
 
 
 CD45RB
 
high
 
 T cells into SCID mice (22).
Is the study of Feng et al. relevant to the pathogenesis of
type 1 diabetes? Evidence so far suggests that LFA-1 and 
 
 
 
4
integrin play dominant roles in initial penetration of T cells
into the islets in murine models of this disease. The histol-
ogy of pancreata of ICAM-1
 
 
 
/
 
 
 
 
 
NOD/IL-10 transgenic
mice and of NOD mice treated with blocking antibodies to
 
 
 
4, 
 
 
 
2, and 
 
 
 
7 integrins and their respective ligands,
VCAM-1, ICAM-1, and MAdCAM-1, bears a striking re-
semblance to that of the healthy allografts in the study by
Feng et al. T cells surround but do not penetrate the islets
(23, 24). Few T cells infiltrating the pancreas in NOD mice
express CD103 (25), consistent with a greater importance
 
Table I. 
 
Integrin Other names Principal ligands
 
 
 
E
 
 
 
7 CD103, 
 
 
 
IEL, HML-1, 
 
 
 
M290 E-cadherin
 
 
 
4
 
 
 
7 LPAM-1 MAdCAM-1 
 
 
 
4
 
 
 
1 CD49d/CD29, VLA-4 VCAM-1, fibronectin
 
 
 
L
 
 
 
2 CD11a/CD18, LFA-1 ICAM-1, -2, -3, -4, -5 
875
 
Kilshaw and Higgins
 
of these other adhesion systems. However, given the
present results, the potential contribution of CD103 at an
early stage of disease warrants further attention.
The paper by Feng et al. serves as timely reminder that
when T cells, TGF-
 
 
 
, and E-cadherin coexist in a tissue
microenvironment, CD103 function deserves a close look.
One can envisage several situations in which CD103 inhib-
itors could be of therapeutic value. The benefits will de-
pend on the extent to which epithelial cell destruction is
involved in rejection or loss of organ function. This type of
intervention may be useful as an adjunct to other strategies.
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